Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Roberto Giacomelli, Antonella Afeltra, Alessia Alunno, Elena Bartoloni-Bocci, Onorina Berardicurti, Michele Bombardieri, Alessandra Bortoluzzi, Roberto Caporali, Francesco Caso, Ricard Cervera, Maria Sole Chimenti, Paola Cipriani, Emmanuel Coloma, Fabrizio Conti, Salvatore D'Angelo, Salvatore De Vita, Salvatore Di Bartolomeo, Oliver Distler, Andrea Doria, Eugen Feist & 21 others Benjamin A. Fisher, Maria Gerosa, Michele Gilio, Giuliana Guggino, Vasiliki Liakouli, Domenico Paolo Emanuele Margiotta, Pierluigi Meroni, Gianluca Moroncini, Federico Perosa, Marcella Prete, Roberta Priori, Chiara Rebuffi, Piero Ruscitti, Raffaele Scarpa, Yehuda Shoenfeld, Monica Todoerti, Francesco Ursini, Guido Valesini, Serena Vettori, Claudio Vitali, Athanasios G. Tzioufas

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.

Original languageEnglish
JournalAutoimmunity Reviews
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Rheumatic Diseases
Autoimmune Diseases
Biomarkers
Guidelines
Complement Activation
Therapeutics
Early Diagnosis
Immune System
Cytokines
Inflammation

Keywords

  • Antiphospholipid syndrome
  • Biomarker
  • Rheumatoid arthritis
  • Sjögren syndrome
  • Spondyloarthritides
  • Systemic lupus erythematosus
  • Systemic sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Giacomelli, R., Afeltra, A., Alunno, A., Bartoloni-Bocci, E., Berardicurti, O., Bombardieri, M., ... Tzioufas, A. G. (Accepted/In press). Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews. https://doi.org/10.1016/j.autrev.2018.08.003

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. / Giacomelli, Roberto; Afeltra, Antonella; Alunno, Alessia; Bartoloni-Bocci, Elena; Berardicurti, Onorina; Bombardieri, Michele; Bortoluzzi, Alessandra; Caporali, Roberto; Caso, Francesco; Cervera, Ricard; Chimenti, Maria Sole; Cipriani, Paola; Coloma, Emmanuel; Conti, Fabrizio; D'Angelo, Salvatore; De Vita, Salvatore; Di Bartolomeo, Salvatore; Distler, Oliver; Doria, Andrea; Feist, Eugen; Fisher, Benjamin A.; Gerosa, Maria; Gilio, Michele; Guggino, Giuliana; Liakouli, Vasiliki; Margiotta, Domenico Paolo Emanuele; Meroni, Pierluigi; Moroncini, Gianluca; Perosa, Federico; Prete, Marcella; Priori, Roberta; Rebuffi, Chiara; Ruscitti, Piero; Scarpa, Raffaele; Shoenfeld, Yehuda; Todoerti, Monica; Ursini, Francesco; Valesini, Guido; Vettori, Serena; Vitali, Claudio; Tzioufas, Athanasios G.

In: Autoimmunity Reviews, 01.01.2018.

Research output: Contribution to journalArticle

Giacomelli, R, Afeltra, A, Alunno, A, Bartoloni-Bocci, E, Berardicurti, O, Bombardieri, M, Bortoluzzi, A, Caporali, R, Caso, F, Cervera, R, Chimenti, MS, Cipriani, P, Coloma, E, Conti, F, D'Angelo, S, De Vita, S, Di Bartolomeo, S, Distler, O, Doria, A, Feist, E, Fisher, BA, Gerosa, M, Gilio, M, Guggino, G, Liakouli, V, Margiotta, DPE, Meroni, P, Moroncini, G, Perosa, F, Prete, M, Priori, R, Rebuffi, C, Ruscitti, P, Scarpa, R, Shoenfeld, Y, Todoerti, M, Ursini, F, Valesini, G, Vettori, S, Vitali, C & Tzioufas, AG 2018, 'Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis', Autoimmunity Reviews. https://doi.org/10.1016/j.autrev.2018.08.003
Giacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Berardicurti O, Bombardieri M et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews. 2018 Jan 1. https://doi.org/10.1016/j.autrev.2018.08.003
Giacomelli, Roberto ; Afeltra, Antonella ; Alunno, Alessia ; Bartoloni-Bocci, Elena ; Berardicurti, Onorina ; Bombardieri, Michele ; Bortoluzzi, Alessandra ; Caporali, Roberto ; Caso, Francesco ; Cervera, Ricard ; Chimenti, Maria Sole ; Cipriani, Paola ; Coloma, Emmanuel ; Conti, Fabrizio ; D'Angelo, Salvatore ; De Vita, Salvatore ; Di Bartolomeo, Salvatore ; Distler, Oliver ; Doria, Andrea ; Feist, Eugen ; Fisher, Benjamin A. ; Gerosa, Maria ; Gilio, Michele ; Guggino, Giuliana ; Liakouli, Vasiliki ; Margiotta, Domenico Paolo Emanuele ; Meroni, Pierluigi ; Moroncini, Gianluca ; Perosa, Federico ; Prete, Marcella ; Priori, Roberta ; Rebuffi, Chiara ; Ruscitti, Piero ; Scarpa, Raffaele ; Shoenfeld, Yehuda ; Todoerti, Monica ; Ursini, Francesco ; Valesini, Guido ; Vettori, Serena ; Vitali, Claudio ; Tzioufas, Athanasios G. / Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. In: Autoimmunity Reviews. 2018.
@article{be9b936209f84efc9a53275492b9f93b,
title = "Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis",
abstract = "Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50{\%} of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.",
keywords = "Antiphospholipid syndrome, Biomarker, Rheumatoid arthritis, Sj{\"o}gren syndrome, Spondyloarthritides, Systemic lupus erythematosus, Systemic sclerosis",
author = "Roberto Giacomelli and Antonella Afeltra and Alessia Alunno and Elena Bartoloni-Bocci and Onorina Berardicurti and Michele Bombardieri and Alessandra Bortoluzzi and Roberto Caporali and Francesco Caso and Ricard Cervera and Chimenti, {Maria Sole} and Paola Cipriani and Emmanuel Coloma and Fabrizio Conti and Salvatore D'Angelo and {De Vita}, Salvatore and {Di Bartolomeo}, Salvatore and Oliver Distler and Andrea Doria and Eugen Feist and Fisher, {Benjamin A.} and Maria Gerosa and Michele Gilio and Giuliana Guggino and Vasiliki Liakouli and Margiotta, {Domenico Paolo Emanuele} and Pierluigi Meroni and Gianluca Moroncini and Federico Perosa and Marcella Prete and Roberta Priori and Chiara Rebuffi and Piero Ruscitti and Raffaele Scarpa and Yehuda Shoenfeld and Monica Todoerti and Francesco Ursini and Guido Valesini and Serena Vettori and Claudio Vitali and Tzioufas, {Athanasios G.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.autrev.2018.08.003",
language = "English",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",

}

TY - JOUR

T1 - Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

AU - Giacomelli, Roberto

AU - Afeltra, Antonella

AU - Alunno, Alessia

AU - Bartoloni-Bocci, Elena

AU - Berardicurti, Onorina

AU - Bombardieri, Michele

AU - Bortoluzzi, Alessandra

AU - Caporali, Roberto

AU - Caso, Francesco

AU - Cervera, Ricard

AU - Chimenti, Maria Sole

AU - Cipriani, Paola

AU - Coloma, Emmanuel

AU - Conti, Fabrizio

AU - D'Angelo, Salvatore

AU - De Vita, Salvatore

AU - Di Bartolomeo, Salvatore

AU - Distler, Oliver

AU - Doria, Andrea

AU - Feist, Eugen

AU - Fisher, Benjamin A.

AU - Gerosa, Maria

AU - Gilio, Michele

AU - Guggino, Giuliana

AU - Liakouli, Vasiliki

AU - Margiotta, Domenico Paolo Emanuele

AU - Meroni, Pierluigi

AU - Moroncini, Gianluca

AU - Perosa, Federico

AU - Prete, Marcella

AU - Priori, Roberta

AU - Rebuffi, Chiara

AU - Ruscitti, Piero

AU - Scarpa, Raffaele

AU - Shoenfeld, Yehuda

AU - Todoerti, Monica

AU - Ursini, Francesco

AU - Valesini, Guido

AU - Vettori, Serena

AU - Vitali, Claudio

AU - Tzioufas, Athanasios G.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.

AB - Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.

KW - Antiphospholipid syndrome

KW - Biomarker

KW - Rheumatoid arthritis

KW - Sjögren syndrome

KW - Spondyloarthritides

KW - Systemic lupus erythematosus

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85056795154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056795154&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2018.08.003

DO - 10.1016/j.autrev.2018.08.003

M3 - Article

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

ER -